Global Biopharma Hub

Global Biopharma Hub

  • Context:

  • The Union Budget 2026-27 has signalled a decisive shift in India's pharmaceutical strategy, moving beyond generic medicines to position the country as a global hub for Biopharmaceuticals.

  • This is anchored by the new Biopharma SHAKTI initiative

  • About Biopharmaceuticals:

  • Unlike traditional chemical drugs (synthesized chemically), biopharmaceuticals are medicines produced using living biological systems such as human cells, fungi, or microbes.

  • They are structurally more complex and targeted than conventional drugs, interacting precisely with biological pathways.

  • Examples include Vaccines, gene therapies, antibody treatments, modern insulin, and biosimilars.

  • These are essential for treating non-communicable diseases where traditional drugs may be less effective

  • Key Initiatives & Schemes:

  • Biopharma SHAKTI:

  • The total outlay is ₹10,000 crores over five years.

  • The objective is to strengthen the end-to-end ecosystem for biologics and biosimilars, reduce import dependence, and enhance global competitiveness.

  • The goal is to capture 5% of the global biopharmaceutical market share.

  • Components:

  • Establishment of three new National Institutes of Pharmaceutical Education and Research (NIPERs) and upgradation of seven existing ones to create specialized human resources.

  • Development of over 1,000 accredited clinical trial sites to accelerate innovation and ethical trials.

  • Strengthening the Central Drugs Standard Control Organisation (CDSCO) with specialized scientific personnel to align approval timelines with global standards.

  • National Biopharma Mission (NBM)-"Innovate in India (i3)":

  • It was launched in 2017 with a focus on vaccines, bio-therapeutics, and diagnostics.

  • It is co-funded by the World Bank and implemented by BIRAC (Biotechnology Industry Research Assistance Council).

  • It supported the development of indigenous products like the ZyCoV-D (DNA-based COVID-19 vaccine) and India's first MRI scanner (Voxel Grids).

  • BioE3 Policy:

  • It focuses on "Biotechnology for Economy, Environment and Employment," promoting biomanufacturing and biofoundries for a sustainable future.

  • Bio-RIDE Scheme:

  • Merges existing DBT schemes to support R&D and industrial entrepreneurship with an outlay of ₹9,197 crore.